Basking Biosciences Inc

🚀 Exciting news! Just landed in Sydney, for another incredible journey across Australia! Over the coming weeks, CEO Rich Shea and local head of operations Barbara Kienast will be meeting with investigative sites, vendor partners, and colleagues to further our clinical trial activities in the evaluation of BB-031 for acute ischemic stroke.   We’re committed to driving innovation to improve patient lives.   #ClinicalTrials #Australia #Research #AIS

Our CEO Rich Shea was honored to participate in Don Alexander, CPC's “Executive Insights for Life Sciences Innovators” webcast series. 🎥Watch as Rich shares his journey from serving as a United States submarine officer to biotech CEO, highlighting the parallels between the two. He also reflects on his first exposure to the pharmaceutical industry and the opportunity it provides to embrace a mission bigger than yourself, making a meaningful difference in people’s lives. He reviews the continuing high unmet need in acute thrombosis, despite advancements in treatment over the last 20 years, and emphasizes the importance of Basking’s reversible thrombolytic development program to address these challenges.   Plus, don’t miss his advice to new start-ups navigating the fundraising journey!   #ExecutiveInsights #LifeSciences #Innovators #Insights https://lnkd.in/e5adCMwq

🧠 We truly enjoyed connecting with our esteemed investigators and colleagues at last week's International Stroke Conference (#ISC25) as we advance our Phase 2 RAISE trial in patients with acute ischemic stroke. #Collaboration #CriticalNeed #Phase2 #PatientsAreWaiting

Is it time to re-visit our understanding of clot formation, contraction and reperfusion? Should our approach to stroke care involve disaggregating blood clots by targeting von Willebrand Factor, rather than dissolving fibrin? Basking co-founder and Chief Medical Officer Shahid Nimjee, M.D., sat down with interventional cardiologist C. Michael Gibson, M.S., M.D. to discuss Basking’s revolutionary approach to treat ischemic stroke and the potential of von Willebrand Factor to safely target large vessel occlusion while also preventing downstream hemorrhages. Here’s an excerpt from that conversation. Watch the full Clinical Trial Results interview: http://bit.ly/40l2VJ8 #drugdevelopment #clinicaltrials #neurology #vWF #Stroke #PatientsAreWaiting

Thanks. So grateful for this incredible team and the dedication they bring to our mission every day. Excited for all we will achieve together in 2025!

✨Together Again! What a fantastic way to kick off 2025! The team gathered for a celebratory dinner and another engaging and productive work session — brainstorming and planning for the year ahead! Members joined from Australia, Singapore, Baltimore, Texas, Ohio and North Carolina. Here’s to collaboration, innovation and success! #Teamwork #2025Goals #PatientsAreTheReason

🎥 Discover the science of stroke treatment! Our new Mechanism of Action (MoA) animation reveals how BB-031, our RNA aptamer, targets von Willebrand Factor (vWF) to dissolve blood clots. By breaking down the outer shell and then destabilizing the core, BB-031 is designed to restore blood flow in acute ischemic stroke. ▶️ Watch our novel #thrombolytic in action on our updated website: https://shorturl.at/nmMzN #drugdevelopment  #clinicaltrials #neurology #vWF #AIS #Stroke

💊 #DYK: There’s only one drug approved in the US to treat stroke, yet it’s only available to a fraction of patients? Of the 800,000 ischemic strokes each year, only 7% (around 50,000 patients) are able to be treated with tPA (tissue plasminogen activator) because it must be given within 4.5 hours of stroke onset. And while small, a not insignificant subset of the patients will experience brain bleeds. What about mechanical thrombectomy? While its emergence has been remarkable over the last decade, gaps in treatment still remain as they only address large vessel occlusion stroke. It's time to address the limitations in stroke care and Basking's lead drug candidate BB-031 is being evaluated to do just that. By going after von Willebrand Factor rather than fibrin, Basking’s approach addresses the care shortfalls to target clot integrity and expand the therapeutic time window. Our co-founder and Chief Medical Officer, @Shahid Nimjee, and our Scientific and Clinical Advisory Board member, @Ashutosh Jadhav, recently shared their insights on the future of stroke care with @NeuroNews.  📚Read the full article to learn more about our reversible thrombolytic BB-031. #drugdevelopment #clinicaltrials #neurology #vWF #AIS #Stroke

We are thrilled to be training our investigative colleagues in sunny San Diego this week ahead of their participation in the RAISE trial! 🌏 We’re grateful to everyone who attended our information-filled workshops while at The Society of Vascular and Interventional Neurology #SVIN24 annual meeting. Together, we can revolutionize stroke care. 💡 Visit https://lnkd.in/gr6B3Twz to find out more about the Phase 2 clinical trial assessing BB-031 in patients who present with acute ischemic stroke. #AIS #stroke #clinicaltrials #RAISEtrial #Basking

🧠 World Stroke Day 2024 🧠 Each year, 15 million people suffer a stroke, with acute ischemic stroke making up 87% of all cases. On #WorldStrokeDay, we are reminded of the critical need for innovative therapies that can extend the treatment window, increase access and improve outcomes for stroke patients. At Basking Biosciences, we’re committed to advancing BB-031, a novel thrombolytic therapy that targets von Willebrand Factor (#vWF) to dissolve clots safely and effectively beyond the 4.5-hour window and expanding treatment options for the 80-85% of stroke patients who currently have no available acute therapy. We’re excited to be evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of BB-031 in patients with acute ischemic stroke in our RAISE clinical trial. 🔗 Learn more: https://lnkd.in/gr6B3Twz #drugdiscovery #drugdevelopment #clinicaltrials #phase2 #neurology #vWF #AIS #Stroke #GreaterThan #WorldStrokeDay